Clinical implications of T cell exhaustion for cancer immunotherapy
Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …
mRNA-based therapeutics: powerful and versatile tools to combat diseases
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
Chimeric antigen receptor (CAR) T cell expansion and persistence represent key factors to
achieve complete responses and prevent relapses. These features are typical of early …
achieve complete responses and prevent relapses. These features are typical of early …
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive
relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It …
relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It …
Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - Journal of hematology & …, 2020 - Springer
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
Mechanisms of resistance to CAR T cell therapy
The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
S Feins, W Kong, EF Williams… - American journal of …, 2019 - Wiley Online Library
Chimeric antigen receptor (CAR) T‐cell therapy represents a major advancement in
personalized cancer treatment. In this strategy, a patient's own T cells are genetically …
personalized cancer treatment. In this strategy, a patient's own T cells are genetically …
Scalable manufacturing of CAR T cells for cancer immunotherapy
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
cell therapies for hematologic malignancies. With the current transition of CAR T cell …
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials
in relapsed patients to a viable therapeutic approach with predictable efficacy and low …
in relapsed patients to a viable therapeutic approach with predictable efficacy and low …